Evidence map›Paper›PMID 20677560›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2010

[The systemic evaluation and clinical significance of immunological function for advanced lung cancer patients].

Tuya Wulan, Shiyong Wang, Weili Du, Hui Zhang, Yuan Zhang, Xue Zeng, Sa Liu, Yanping Liu, Lu Zhang, Zhe Zhang and 3 more

Open access · greenAbstract readEnglish Abstract
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Tuya WulanDepartment of Biotherapy, Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
Shiyong Wang
Weili Du
Hui Zhang
Yuan Zhang
Xue Zeng
Sa Liu
Yanping Liu
Lu Zhang
Zhe Zhang
Ying He
Jialing Wang
Xiuyan Wu
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe actual evaluation of immunological function is significant for studing the tumor development and devising a treatment in time. The aim of this study is to evaluate the immunological function of advanced lung cancer patients systematically, and to discuss the clinical significance.

methodsThe nucleated cell amounts of advanced lung cancer patients and the healthy individuals were counted. The immune cell subsets and the levels of IL-4, INF-gamma, perforin and granzyme in CD8+T cells by the flow cytometry were measured. The proliferation activity and the inhibition ratio of immune cells to several tumor cell lines were evaluated by MTT assay.

resultsThe absolute amounts and subsets of T, B, NK cells of advanced lung cancer patients were lower than the healthy individuals (P < 0.05); However, the proportion of regulatory T cells of advanced lung cancer patients (4.00 +/- 1.84)% was lower than the healthy individuals (1.27 +/- 0.78)% (P < 0.05). The positive rates of IFN-gamma perforin, granzyme in CD8+T cells decreased while them in IL-4 did not in the advanced lung cancer patients compared to the healthy control group (P < 0.05). The proliferation activity of immune cells, the positive rate of PPD masculine and the inhibition ratio to tumor cells in the advanced lung cancer patients was lower than the healthy subsets obviously (P < 0.05).

conclusionThere was a significant immune depression in the advanced lung cancer patients compared to the healthy individuals.

Indexed as

AdultAgedCD8-Positive T-LymphocytesCell Line, TumorFemaleFlow CytometryGranzymesHumansInterferon-gammaInterleukin-4Lung NeoplasmsMaleMiddle AgedPerforinGranzymesInterferon-gammaInterleukin-4Perforin

Identifiers

PMID20677560
PMCPMC6000421
OpenAlexW1513188572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.